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Activin and BMP Signaling Mechanics in Myogenic Cells 
 
Timothy Cho and Jonathan W. Lowery 
Division of Biomedical Science, Marian University College of Osteopathic Medicine, Indianapolis, IN, USA 
The Activin and BMP signaling pathways exert reciprocal effects on myogenesis and skeletal muscle 
regeneration after injury. Signal transduction in both pathways is mediated by ligand-induced activation of 
transcriptional regulators called SMAD proteins, with Activins leading to phosphorylation of SMAD2/3 and 
BMPs leading to phosphorylation of SMAD1/5/8. These ligands bind to their own type I receptors but can 
also compete for shared type II receptors (ACVR2A and/or ACVR2B). However, it is unclear how these 
pathways interact in skeletal muscle progenitor cells. To address this deficiency, we investigated the effects 
of the ligands BMP2 and Activin-A on C2C12 cells, which are an immortalized mouse myoblast cell line with 
myogenic potential, using a sequence of pre-treatment and co-treatment assays followed by western blot 
analyses to examine the activation level of their respective SMAD proteins. As expected, treatment with 
exogenous BMP2 or Activin-A led to phosphorylation of SMAD1/5/8 and SMAD2/3, respectively. Moreover, 
pre-treatment of C2C12 cells with Activin-A before BMP2 delivery resulted in an attenuated 
phosphorylation of SMAD1/5/8; this effect seems to be specific to Activin ligands, though, since the 
converse relationship was not observed with respect to phosphorylation of SMAD2/3. Similarly, attenuated 
phosphorylation of SMAD 1/5/8 was also observed when Activin-A and BMP2 were delivered to C2C12 cells 
simultaneously; this co-treatment scenario results in a lower level of SMAD1/5/8 phosphorylation indicating 
competition for receptor binding between the two ligands. Ongoing experiments seek to elucidate the 
mechanism(s) impacting the cellular responses under sequential versus simultaneous activation by Activin 
and BMP ligands. A better understanding of these mechanisms could lead to novel therapeutic strategies for 
regeneration of skeletal muscle tissue after injury. 
Figure 1: Signaling schematic of BMP and Activin signaling pathways. Type I receptors, ALK2/3/6 and ALK4/7 
are specific to BMP and Activin binding, respectively. ACVR2A/B, a type II receptor, is shared between the 
two ligands. Binding of the type II receptor causes dimerization of the receptors and results in 
phosphorylation of respective SMAD proteins.  
Figure 2: Single treatment assay of 
C2C12 cells with BMP2 and Activin-A 
ligands. Increasing doses of each ligand 
concentration (from 10 ng/ml, 50 ng/ml, 
and 100 ng/ml) were introduced. B-
actin, total SMAD1, and total SMAD2 
serve as loading controls.  
Figure 3: Pre-treatment assays of C2C12 cells 
with BMP2 and Activin-A ligands. Max doses 
(100 ng/ml) of each ligand were introduced: 
first ligand (for 5 minutes) and second ligand 
(for 30 minutes). B-actin, total SMAD1, and 
total SMAD2 serve as loading controls. 
Conclusions: 
• Treatment with exogenous BMP2 or Activin-A led to phosphorylation of 
SMAD1/5/8 and SMAD2/3, respectively. 
• Pre-treatment with Activin-A before BMP2 delivery resulted in attenuated 
phosphorylation of SMAD1/5/8; converse relationship not observed with respect 
to phosphorylation of SMAD2/3 
• Co-treatment with Activin-A and BMP2 resulted in attenuated phosphorylation of 
SMAD1/5/8 indicating competition for receptor-binding 
 
Future studies: 
• Repeat current study to verify the indicated results 
• Introduce myogenic assays to assess the functional capacity for myogenesis in 
C2C12 cells 
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Figure 4: Co-treatment assay of 
C2C12 cells with BMP2 and 
Activin-A ligands. Max doses 
(100 ng/ml) of each ligand were 
introduced. B-actin serves as 
loading control. 
